@article{article_1024525, title={Mesenchymal Stem Cell Therapy in Severe COVID-19 in a Young Male Healthcare Worker with Tetralogy of Fallot}, journal={Journal of Anatolian Medical Research}, volume={7}, pages={26–30}, year={2022}, author={Yüksel, Recep Civan and Eren, Esma and Ulu Kılıç, Ayşegül and Çelik, İlhami}, keywords={Mesenchymal Stem Cell, COVID19, HFNO}, abstract={<p>A novel type of coronavirus (SARS-CoV-2), which causesevere acute respiratory syndrome, wasfirst identified in Wuhan, <br />China at the end of December 2019 and the disease rapidly spread worldwide. COVID-19 may be characterized by a <br />range of symptoms, mild illness to severe pneumoniae. Cardiovascular diseases increase severity and mortality in COVID-19 <br />patients. Tetralogy of Fallot is the most common cyanotic congenital heart disease. The present case is an adult COVID-19 <br />patient with a history of Tetralogy of Fallot, who is a healthcare worker. High Flow Nasal Oxygen therapy was used due to <br />respiratory distress. In addition, Mesenchymal Stem Cells were applied while the disease was in critical process. The clinical <br />and laboratory improvement were observed in the patient from the second day of treatment of Mesenchymal Stem Cells. The <br />young healthcare worker with a history of Tetralogy of Fallot needed critical care due to COVID-19. Response to the antiviral <br />treatments given to the patient could not be obtained. High Flow Nasal Oxygen and Mesenchymal Stem Cells were used in <br />the treatment of the patient. </p>}, number={1}, publisher={Kayseri Şehir Eğitim ve Araştırma Hastanesi}